P
Philippe Solal-Celigny
Researcher at University of Minnesota
Publications - 113
Citations - 14315
Philippe Solal-Celigny is an academic researcher from University of Minnesota. The author has contributed to research in topics: Follicular lymphoma & Rituximab. The author has an hindex of 45, co-authored 113 publications receiving 13476 citations.
Papers
More filters
Journal ArticleDOI
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
Guillaume Cartron,Laurent Dacheux,Gilles Salles,Philippe Solal-Celigny,Pierre Bardos,Philippe Colombat,Hervé Watier +6 more
TL;DR: This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab, and will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
P. Feugier,A. Van Hoof,Catherine Sebban,Philippe Solal-Celigny,R. Bouabdallah,Christophe Fermé,B. Christian,Eric Lepage,H. Tilly,F. Morschhauser,Philippe Gaulard,Gilles Salles,André Bosly,Christian Gisselbrecht,Felix Reyes,B. Coiffier +15 more
TL;DR: Using the combination of R-CHOP leads to significant improvement of the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefit maintained during a 5-year follow-up.
Journal ArticleDOI
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
Robert Marcus,Kevin Imrie,Andrew R. Belch,David Cunningham,Eduardo Flores,John Catalano,Philippe Solal-Celigny,Fritz Offner,Jan Walewski,João Raposo,Andrew Jack,Paul Smith +11 more
TL;DR: The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity.
Journal ArticleDOI
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico,Monica Bellei,Luigi Marcheselli,Stefano Luminari,Armando López-Guillermo,Umberto Vitolo,Barbara Pro,Stefano Pileri,Alessandro Pulsoni,Pierre Soubeyran,Sergio Cortelazzo,Giovanni Martinelli,Maurizio Martelli,Luigi Rigacci,Luca Arcaini,Francesco Di Raimondo,Francesco Merli,Elena Sabattini,Peter McLaughlin,Philippe Solal-Celigny +19 more
TL;DR: Follicular Lymphoma International Prognostic Index 2 is a simple prognostic index based on easily available clinical data and may represent a promising new tool for the identification of patients with FL at different risk in the era of immunochemotherapy.